ALX ONCOLOGY HOLDINGS INC

ALXO is the ticker symbol for ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company. It trades on the Nasdaq under the symbol ALXO. The company focuses on developing therapies that block the CD47 checkpoint pathway to help the immune system fight cancer. Because it is clinical-stage, its value is tied to research progress, trial results, and regulatory developments.

Recent performance for ALXO can be found in the price chart and performance data shown on this page. Clinical-stage biotech stocks like ALXO often move on trial updates, financing news, and sector sentiment, so performance can vary widely over short periods. For the latest percentage changes and historical price action, refer to the current ALXO data displayed here.

Determining whether ALXO is overvalued or undervalued requires comparing its market capitalization and cash position against its clinical pipeline prospects, since the company may not yet have commercial revenue. Valuation for clinical-stage biotechs often depends on projected trial success and potential market opportunities rather than traditional earnings multiples. Use the valuation metrics and financial data provided on this page for the latest context.

ALXO may be available for trading in pre-market and after-hours sessions, depending on your broker and the venue. These sessions generally have lower liquidity and wider spreads than regular Nasdaq trading hours. Not all brokers support extended-hours trading for ALXO, so confirm availability with your brokerage before placing orders outside the standard session.

ALXO does not currently pay a dividend. As a clinical-stage biopharmaceutical company, it typically reinvests capital into research, development, and clinical trials rather than returning cash to shareholders through dividends. For the most current dividend status, check the dividend information section on this page.

Key risks include clinical trial failures or delays, regulatory setbacks, and the need for additional financing, which can dilute existing shareholders. As a clinical-stage company, ALXO may have limited or no product revenue, and its stock price can be volatile around data readouts or partnership news. Competitive pressures and changes in healthcare policy can also affect its prospects.